Skip to main content

Articles

Page 1 of 104

  1. Sentinel lymph node biopsy (SLNB) is recommended for patients with ductal carcinoma in situ (DCIS) undergoing mastectomy, given the concerns regarding upstaging and technical difficulties of post-mastectomy SL...

    Authors: Soong June Bae, Yoonwon Kook, Ji Soo Jang, Seung Ho Baek, Sohyun Moon, Jung Hyun Kim, Seung Eun Lee, Min Ji Kim, Sung Gwe Ahn and Joon Jeong
    Citation: Breast Cancer Research 2024 26:65
  2. This study aimed to explore potential indicators associated with the neoadjuvant efficacy of TCbHP regimen (taxane, carboplatin, trastuzumab, and pertuzumab) in HER2 + breast cancer (BrCa) patients.

    Authors: Ningning Zhang, Yuxin Huang, Guanwen Wang, Yimei Xiang, Zhouhong Jing, Junjie Zeng, Feng Yu, Xianjun Pan, Wenqi Zhou and Xiaohua Zeng
    Citation: Breast Cancer Research 2024 26:64
  3. Chitinase-like proteins (CLPs) play a key role in immunosuppression under inflammatory conditions such as cancer. CLPs are enzymatically inactive and become neutralized upon binding of their natural ligand chi...

    Authors: Robbe Salembier, Caro De Haes, Julie Bellemans, Kristel Demeyere, Wim Van Den Broeck, Niek N. Sanders, Steven Van Laere, Traci R. Lyons, Evelyne Meyer and Jonas Steenbrugge
    Citation: Breast Cancer Research 2024 26:63
  4. Breast cancers exhibit considerable heterogeneity in their biology, immunology, and prognosis. Currently, no validated, serum protein-based tools are available to evaluate the prognosis of patients with early ...

    Authors: Peeter Karihtala, Suvi-Katri Leivonen, Ulla Puistola, Elina Urpilainen, Anniina Jääskeläinen, Sirpa Leppä and Arja Jukkola
    Citation: Breast Cancer Research 2024 26:61
  5. Small nucleolar RNAs (snoRNAs) play key roles in ribosome biosynthesis. However, the mechanism by which snoRNAs regulate cancer stemness remains to be fully elucidated.

    Authors: Wenrong Zhang, Xinyue Song, Zining Jin, Yiqi Zhang, Shan Li, Feng Jin and Ang Zheng
    Citation: Breast Cancer Research 2024 26:60
  6. Patients with hormone receptor positive breast cancer are recommended at least five years of adjuvant endocrine therapy, but adherence to this treatment is often suboptimal. We investigated longitudinal trends...

    Authors: Kirsten M. Woolpert, Julie A. Schmidt, Thomas P. Ahern, Cathrine F. Hjorth, Dóra K. Farkas, Bent Ejlertsen, Lindsay J. Collin, Timothy L. Lash and Deirdre P. Cronin-Fenton
    Citation: Breast Cancer Research 2024 26:59
  7. Authors: Muhammad Hasan Bashari, Fengjuan Fan, Sonia Vallet, Martin Sattler, Melissa Arn, Claudia Luckner-Minden, Henning Schulze-Bergkamen, Inka Zörnig, Frederik Marme, Andreas Schneeweiss, Michael H. Cardone, Joseph T. Opferman, Dirk Jäger and Klaus Podar
    Citation: Breast Cancer Research 2024 26:58

    The original article was published in Breast Cancer Research 2016 18:26

  8. Breast cancer continues to pose a substantial worldwide health concern, demanding a thorough comprehension of the complex interaction between cancerous cells and the immune system. Recent studies have shown th...

    Authors: Sahar Safaei, Manouchehr Fadaee, Omid Rahbar Farzam, Amirhossein Yari, Elham Poursaei, Cynthia Aslan, Sahar Samemaleki, Dariush Shanehbandi, Behzad Baradaran and Tohid Kazemi
    Citation: Breast Cancer Research 2024 26:57
  9. Patient-derived organoid models of estrogen receptor-positive (ER+) breast cancer would provide a much-needed tool to understand drug resistance and disease progression better. However, the establishment and l...

    Authors: Michael U J Oliphant, Dipikaa Akshinthala and Senthil K. Muthuswamy
    Citation: Breast Cancer Research 2024 26:56
  10. Breast cancer-related leptomeningeal disease (BC-LMD) is a dire diagnosis for 5–8% of patients with breast cancer (BC). We conducted a retrospective review of BC-LMD patients diagnosed at Moffitt Cancer Center...

    Authors: Gerald Wallace, Ronak Kundalia, Ethan Vallebuona, Biwei Cao, Youngchul Kim, Peter Forsyth, Aixa Soyano, Inna Smalley and Yolanda Pina
    Citation: Breast Cancer Research 2024 26:55
  11. Fibroblast growth factors (FGFs) control various cellular functions through fibroblast growth factor receptor (FGFR) activation, including proliferation, differentiation, migration, and survival. FGFR amplific...

    Authors: Feng Chi, Jason I. Griffiths, Aritro Nath and Andrea H. Bild
    Citation: Breast Cancer Research 2024 26:54
  12. Authors: Jing Qian, Yanxia Ma, William M. Tahaney, Cassandra L. Moyer, Amanda Lanier, Jamal Hill, Darian Coleman, Negar Koupaei, Susan G. Hilsenbeck, Michelle I. Savage, Brent D. G. Page, Abhijit Mazumdar and Powel H. Brown
    Citation: Breast Cancer Research 2024 26:53

    The original article was published in Breast Cancer Research 2024 26:23

  13. Benign breast disease (BBD) and high mammographic breast density (MBD) are prevalent and independent risk factors for invasive breast cancer. It has been suggested that temporal changes in MBD may impact futur...

    Authors: Maeve Mullooly, Shaoqi Fan, Ruth M. Pfeiffer, Erin Aiello Bowles, Máire A. Duggan, Roni T. Falk, Kathryn Richert-Boe, Andrew G. Glass, Teresa M. Kimes, Jonine D. Figueroa, Thomas E. Rohan, Mustapha Abubakar and Gretchen L. Gierach
    Citation: Breast Cancer Research 2024 26:52
  14. Although several transcriptome-wide association studies (TWASs) have been performed to identify genes associated with overall breast cancer (BC) risk, only a few TWAS have explored the differences in estrogen ...

    Authors: Julian C. McClellan, James L. Li, Guimin Gao and Dezheng Huo
    Citation: Breast Cancer Research 2024 26:51
  15. Survivin/BIRC5 is a proliferation marker that is associated with poor prognosis in breast cancer and an attractive therapeutic target. However, BIRC5 has not been well studied among racially diverse population...

    Authors: Alina M. Hamilton, Andrea Walens, Sarah C. Van Alsten, Linnea T. Olsson, Joseph Nsonwu-Farley, Xiaohua Gao, Erin L. Kirk, Charles M. Perou, Lisa A. Carey, Melissa A. Troester and Yara Abdou
    Citation: Breast Cancer Research 2024 26:50
  16. Patient-derived xenograft (PDX) models serve as a valuable tool for the preclinical evaluation of novel therapies. They closely replicate the genetic, phenotypic, and histopathological characteristics of prima...

    Authors: Jongwon Lee, GunHee Lee, Hye Seon Park, Byung-Kwan Jeong, Gyungyub Gong, Jae Ho Jeong and Hee Jin Lee
    Citation: Breast Cancer Research 2024 26:49
  17. Breast cancer stem cell (CSC) expansion results in tumor progression and chemoresistance; however, the modulation of CSC pluripotency remains unexplored. Transmembrane protein 120B (TMEM120B) is a newly discov...

    Authors: Ran Hu, Yu Cao, Yuanyuan Wang, Tingting Zhao, Kaibo Yang, Mingwei Fan, Mengyao Guan, Yuekang Hou, Jiao Ying, Xiaowen Ma, Ning Deng, Xun Sun, Yong Zhang and Xiupeng Zhang
    Citation: Breast Cancer Research 2024 26:48
  18. Breast cancer-related lymphedema is currently one of the most serious complications that most affect the quality of life of women undergoing breast cancer. The aim of this study was to explore in-depth the exp...

    Authors: Laura González-Fernández, Carlos Romero-Morales, Beatriz Martínez-Pascual, Angela Río-González, Ester Cerezo-Téllez and Inmaculada López-Martín
    Citation: Breast Cancer Research 2024 26:47
  19. Authors: Rebecca A. Shatsky, Hemali Batra-Sharma, Teresa Helsten, Richard B. Schwab, Emily I. Pittman, Minya Pu, Elizabeth Weihe, Emanuela M. Ghia, Laura Z. Rassenti, Alfredo Molinolo, Betty Cabrera, James B. Breitmeyer, George F. Widhopf II, Karen Messer, Catriona Jamieson, Thomas J. Kipps…
    Citation: Breast Cancer Research 2024 26:46

    The original article was published in Breast Cancer Research 2024 26:32

  20. Breast density (BD) is a strong risk factor for breast cancer. Little is known about how BD develops during puberty. Understanding BD trajectories during puberty and its determinants could be crucial for promo...

    Authors: Ana Pereira, María Luisa Garmendia, Valeria Leiva, Camila Corvalán, Karin B. Michels and John Shepherd
    Citation: Breast Cancer Research 2024 26:45
  21. Ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) is a deubiquitinating enzyme that regulates ERα expression in triple-negative cancer (TNBC). This study aimed to explore the deubiquitination substrates of UCHL...

    Authors: Juan Li, Yu Liang, Shijie Zhou, Jie Chen and Chihua Wu
    Citation: Breast Cancer Research 2024 26:44
  22. Metastasis is the leading cause of death in breast cancer patients. For metastasis to occur, tumor cells must invade locally, intravasate, and colonize distant tissues and organs, all steps that require tumor ...

    Authors: Sydney J. Conner, Justinne R. Guarin, Thanh T. Le, Jackson P. Fatherree, Charlotte Kelley, Samantha L. Payne, Savannah R. Parker, Hanan Bloomer, Crystal Zhang, Kenneth Salhany, Rachel A. McGinn, Emily Henrich, Anna Yui, Deepti Srinivasan, Hannah Borges and Madeleine J. Oudin
    Citation: Breast Cancer Research 2024 26:43
  23. Breast cancer is the second most common cause of death from cancer in women worldwide. Counterintuitively, large population-based retrospective trials report better survival after breast-conserving surgery (BC...

    Authors: Lotte MC Jacobs, Leonie S Helder, Kim I Albers, Josephine Kranendonk, Christiaan Keijzer, Leo AB Joosten, Luc JA Strobbe and Michiel C Warlé
    Citation: Breast Cancer Research 2024 26:42
  24. Most patients with triple-negative breast cancer (TNBC) are not candidates for targeted therapy, leaving chemotherapy as the primary treatment option. Recently, immunotherapy has demonstrated promising results...

    Authors: Ximena Baez-Navarro, Nadine S. van den Ende, Anh H. Nguyen, Renata Sinke, Pieter Westenend, Johannes Bastiaan van Brakel, Claudia Stobbe, Johan Westerga and Carolien H. M. van Deurzen
    Citation: Breast Cancer Research 2024 26:41
  25. 99mTc radiolabeled nanobody NM-02 (99mTc-NM-02) is a novel single photon emission computed tomography (SPECT) probe with a high affinity and specificity for human epidermal growth factor receptor 2 (HER2). In thi...

    Authors: Lingzhou Zhao, Yan Xing, Changcun Liu, Shaofei Ma, Wenhua Huang, Zhen Cheng and Jinhua Zhao
    Citation: Breast Cancer Research 2024 26:40
  26. Early life factors are important risk factors for breast cancer. The association between weight gain after age 18 and breast cancer risk is inconsistent across previous epidemiologic studies. To evaluate this ...

    Authors: Yunan Han, Ebunoluwa E. Otegbeye, Carrie Stoll, Angela Hardi, Graham A. Colditz and Adetunji T. Toriola
    Citation: Breast Cancer Research 2024 26:39
  27. The clinical utility of gene signatures in older breast cancer patients remains unclear. We aimed to determine signature prognostic capacity in this patient subgroup.

    Authors: Miguel Castresana-Aguirre, Annelie Johansson, Alexios Matikas, Theodoros Foukakis, Linda S. Lindström and Nicholas P. Tobin
    Citation: Breast Cancer Research 2024 26:38
  28. Increasing evidence shows the oncogenic function of FAM83D in human cancer, but how FAM83D exerts its oncogenic function remains largely unclear. Here, we investigated the importance of FAM83D/FBXW7 interactio...

    Authors: Xiaoyu Jiang, Yuli Wang, Lulu Guo, Yige Wang, Tianshu Miao, Lijuan Ma, Qin Wei, Xiaoyan Lin, Jian-Hua Mao and Pengju Zhang
    Citation: Breast Cancer Research 2024 26:37
  29. Hyperglycemia is an on-target effect of PI3Kα inhibitors. Early identification and intervention of treatment-induced hyperglycemia is important for improving management of patients receiving a PI3Kα inhibitor ...

    Authors: Jordi Rodón, David Demanse, Hope S. Rugo, Howard A. Burris, Rafael Simó, Azeez Farooki, Melissa F. Wellons, Fabrice André, Huilin Hu, Dragica Vuina, Cornelia Quadt and Dejan Juric
    Citation: Breast Cancer Research 2024 26:36
  30. Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with a poor prognosis. Doxorubicin is part of standard curative therapy for TNBC, but chemotherapy resistance remains an important cl...

    Authors: Stephen G. Smoots, Anna R. Schreiber, Marilyn M. Jackson, Stacey M. Bagby, Adrian T A. Dominguez, Evan D. Dus, Cameron A. Binns, Morgan MacBeth, Phaedra A. Whitty, Jennifer R. Diamond and Todd M. Pitts
    Citation: Breast Cancer Research 2024 26:35
  31. The role of parathyroid hormone (PTH)-related protein (PTHrP) in breast cancer remains controversial, with reports of PTHrP inhibiting or promoting primary tumor growth in preclinical studies. Here, we provide...

    Authors: Courtney M. Edwards, Jeremy F. Kane, Jailyn A. Smith, Déja M. Grant, Jasmine A. Johnson, Maria A. Hernandez Diaz, Lawrence A. Vecchi III, Kai M. Bracey, Tolu N. Omokehinde, Joseph R. Fontana, Breelyn A. Karno, Halee T. Scott, Carolina J. Vogel, Jonathan W. Lowery, T. John Martin and Rachelle W. Johnson
    Citation: Breast Cancer Research 2024 26:34
  32. Estrogen receptor (ER) positive patients compromise about 70% of breast cancers. Tamoxifen, an antagonist of ERα66 (the classic ER), is the most effective and the standard first-line drug. However, its efficac...

    Authors: Ting Song, Hong Zhang, Qicheng Zhao, Zhiyuan Hu, Ziqian Wang, Yang Song and Zhichao Zhang
    Citation: Breast Cancer Research 2024 26:33
  33. Zilovertamab is a humanized monoclonal antibody targeting ROR1, an onco-embryonic antigen expressed by malignant cells of a variety of solid tumors, including breast cancer. A prior phase 1 study showed that z...

    Authors: Rebecca A. Shatsky, Hemali Batra-Sharma, Teresa Helsten, Richard B. Schwab, Emily I. Pittman, Minya Pu, Elizabeth Weihe, Emanuela M. Ghia, Laura Z. Rassenti, Alfredo Molinolo, Betty Cabrera, James B. Breitmeyer, George F. Widhopf II, Karen Messer, Catriona Jamieson, Thomas J. Kipps…
    Citation: Breast Cancer Research 2024 26:32

    The Correction to this article has been published in Breast Cancer Research 2024 26:46

  34. Accurate classification of breast cancer molecular subtypes is crucial in determining treatment strategies and predicting clinical outcomes. This classification largely depends on the assessment of human epide...

    Authors: Minsun Jung, Seung Geun Song, Soo Ick Cho, Sangwon Shin, Taebum Lee, Wonkyung Jung, Hajin Lee, Jiyoung Park, Sanghoon Song, Gahee Park, Heon Song, Seonwook Park, Jinhee Lee, Mingu Kang, Jongchan Park, Sergio Pereira…
    Citation: Breast Cancer Research 2024 26:31
  35. Overexpression of prostate-specific membrane antigen (PSMA) on the vasculature of triple-negative breast cancer (TNBC) presents a promising avenue for targeted endogenous radiotherapy with [177Lu]Lu-PSMA-I&T. Thi...

    Authors: Amelie Heesch, Alexandru Florea, Jochen Maurer, Pardes Habib, Laura S. Werth, Thomas Hansen, Elmar Stickeler, Sabri E. M. Sahnoun, Felix M. Mottaghy and Agnieszka Morgenroth
    Citation: Breast Cancer Research 2024 26:30
  36. Neoadjuvant chemotherapy (NAC) is the standard of care for patients with early-stage triple negative breast cancers (TNBC). However, more than half of TNBC patients do not achieve a pathological complete respo...

    Authors: Françoise Derouane, Manon Desgres, Camilla Moroni, Jérôme Ambroise, Martine Berlière, Mieke R. Van Bockstal, Christine Galant, Cédric van Marcke, Marianela Vara-Messler, Stefan J. Hutten, Jos Jonkers, Larissa Mourao, Colinda L. G. J. Scheele, Francois P. Duhoux and Cyril Corbet
    Citation: Breast Cancer Research 2024 26:29
  37. Despite major therapeutic advances, triple-negative breast cancer (TNBC) still presents a worth prognosis than hormone receptors-positive breast cancers. One major issue relies in the molecular and mutational ...

    Authors: Claire Scheffges, Jérôme Devy, Jérôme Giustiniani, Stessy Francois, Lucille Cartier, Yacine Merrouche, Arnaud Foussat, Stéphane Potteaux, Armand Bensussan and Anne Marie-Cardine
    Citation: Breast Cancer Research 2024 26:28
  38. A malignancy might be found at surgery in cases of atypical ductal hyperplasia (ADH) diagnosed via US-guided core needle biopsy (CNB). The objective of this study was to investigate the diagnostic performance ...

    Authors: Jun Kang Li, Zhi Ying Jin, Yong Jie Xu, Nai Qin Fu, Ying Jiang, Shi Yu Li, Rui Lan Niu, Gang Liu and Zhi Li Wang
    Citation: Breast Cancer Research 2024 26:27
  39. MRI-based tumor shrinkage patterns (TSP) after neoadjuvant therapy (NAT) have been associated with pathological response. However, the understanding of TSP after early NAT remains limited. We aimed to analyze ...

    Authors: Mengfan Wang, Siyao Du, Si Gao, Ruimeng Zhao, Shasha Liu, Wenhong Jiang, Can Peng, Ruimei Chai and Lina Zhang
    Citation: Breast Cancer Research 2024 26:26
  40. There is increasing evidence that artificial intelligence (AI) breast cancer risk evaluation tools using digital mammograms are highly informative for 1–6 years following a negative screening examination. We h...

    Authors: Ruggiero Santeramo, Celeste Damiani, Jiefei Wei, Giovanni Montana and Adam R. Brentnall
    Citation: Breast Cancer Research 2024 26:25
  41. Overexpression of human epidermal growth factor receptor 2 (HER2) caused by HER2 gene amplification is a driver in breast cancer tumorigenesis. We aimed to investigate the prognostic significance of manual sco...

    Authors: Caroline Rönnlund, Emmanouil G. Sifakis, Caroline Schagerholm, Qiao Yang, Emelie Karlsson, Xinsong Chen, Theodoros Foukakis, Jodi Weidler, Michael Bates, Irma Fredriksson, Stephanie Robertson and Johan Hartman
    Citation: Breast Cancer Research 2024 26:24
  42. The most aggressive form of breast cancer is triple-negative breast cancer (TNBC), which lacks expression of the estrogen receptor (ER) and progesterone receptor (PR), and does not have overexpression of the h...

    Authors: Jing Qian, Yanxia Ma, William M. Tahaney, Cassandra L. Moyer, Amanda Lanier, Jamal Hill, Darian Coleman, Negar Koupaei, Susan G. Hilsenbeck, Michelle I. Savage, Brent D. G. Page, Abhijit Mazumdar and Powel H. Brown
    Citation: Breast Cancer Research 2024 26:23

    The Correction to this article has been published in Breast Cancer Research 2024 26:53

  43. One major risk factor for breast cancer is high mammographic density. It has been estimated that dense breast tissue contributes to ~ 30% of all breast cancer. Prevention targeting dense breast tissue has the ...

    Authors: Peter Lundberg, Annelie Abrahamsson, Johan Kihlberg, Jens Tellman, Ieva Tomkeviciene, Anette Karlsson, Maria Kristoffersen Wiberg, Marcel Warntjes and Charlotta Dabrosin
    Citation: Breast Cancer Research 2024 26:22
  44. Patients with inflammatory breast cancer (IBC) have overall poor clinical outcomes, with triple-negative IBC (TN-IBC) being associated with the worst survival, warranting the investigation of novel therapies. ...

    Authors: Filipa Lynce, Laura E. Stevens, Zheqi Li, Jane E. Brock, Anushree Gulvady, Ying Huang, Faina Nakhlis, Ashka Patel, Jeremy M. Force, Tufia C. Haddad, Naoto Ueno, Vered Stearns, Antonio C. Wolff, Amy S. Clark, Jennifer R. Bellon, Edward T. Richardson…
    Citation: Breast Cancer Research 2024 26:20
  45. Human epidermal growth factor receptor 2 (HER2)-positive breast cancer accounts for about 20% of all breast cancer cases and is correlated with a high relapse rate and poor prognosis. ADAMTS18 is proposed as an i...

    Authors: Jiahui Nie, Suying Dang, Rui Zhu, Tiantian Lu and Wei Zhang
    Citation: Breast Cancer Research 2024 26:19
  46. Since breast cancer patients respond diversely to immunotherapy, there is an urgent need to explore novel biomarkers to precisely predict clinical responses and enhance therapeutic efficacy. The purpose of our...

    Authors: Xiaorui Han, Yuan Guo, Huifen Ye, Zhihong Chen, Qingru Hu, Xinhua Wei, Zaiyi Liu and Changhong Liang
    Citation: Breast Cancer Research 2024 26:18
  47. Histological grade is a well-known prognostic factor that is routinely assessed in breast tumours. However, manual assessment of Nottingham Histological Grade (NHG) has high inter-assessor and inter-laboratory...

    Authors: Abhinav Sharma, Philippe Weitz, Yinxi Wang, Bojing Liu, Johan Vallon-Christersson, Johan Hartman and Mattias Rantalainen
    Citation: Breast Cancer Research 2024 26:17
  48. Contralateral breast cancer (CBC) is the most common second primary cancer diagnosed in breast cancer survivors, yet the understanding of the genetic susceptibility of CBC, particularly with respect to common ...

    Authors: Xiaohui Sun, Anne S. Reiner, Anh Phong Tran, Gordon P. Watt, Jung Hun Oh, Lene Mellemkjær, Charles F. Lynch, Julia A. Knight, Esther M. John, Kathleen E. Malone, Xiaolin Liang, Meghan Woods, Andriy Derkach, Patrick Concannon, Jonine L. Bernstein and Xiang Shu
    Citation: Breast Cancer Research 2024 26:16
  49. The birth cohort effect has been suggested to influence the rate of breast cancer incidence and the trends of associated reproductive and lifestyle factors. We conducted a cohort study to determine whether a d...

    Authors: Salma Nabila, Ji-Yeob Choi, Sarah Krull Abe, Md Rashedul Islam, Md Shafiur Rahman, Eiko Saito, Aesun Shin, Melissa A. Merritt, Ryoko Katagiri, Xiao-Ou Shu, Norie Sawada, Akiko Tamakoshi, Ritsu Sakata, Atsushi Hozawa, Jeongseon Kim, Chisato Nagata…
    Citation: Breast Cancer Research 2024 26:15

Annual Journal Metrics

  • 2022 Citation Impact
    7.4 - 2-year Impact Factor
    7.4 - 5-year Impact Factor
    1.764 - SNIP (Source Normalized Impact per Paper)
    2.408 - SJR (SCImago Journal Rank)

    2023 Speed
    20 days submission to first editorial decision for all manuscripts (Median)
    129 days submission to accept (Median)

    2023 Usage 
    2,432,781 downloads
    1,561 Altmetric mentions